These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21317461)

  • 21. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
    Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
    Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombospondin-1-Based Antiangiogenic Therapy.
    Sims JN; Lawler J
    J Ocul Pharmacol Ther; 2015 Sep; 31(7):366-70. PubMed ID: 26352160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.
    Rusk A; McKeegan E; Haviv F; Majest S; Henkin J; Khanna C
    Clin Cancer Res; 2006 Dec; 12(24):7444-55. PubMed ID: 17189418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD36-TSP-HRGP interactions in the regulation of angiogenesis.
    Silverstein RL; Febbraio M
    Curr Pharm Des; 2007; 13(35):3559-67. PubMed ID: 18220792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats.
    Iruela-Arispe ML; Lombardo M; Krutzsch HC; Lawler J; Roberts DD
    Circulation; 1999 Sep; 100(13):1423-31. PubMed ID: 10500044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.
    Welti J; Loges S; Dimmeler S; Carmeliet P
    J Clin Invest; 2013 Aug; 123(8):3190-200. PubMed ID: 23908119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
    Tanaka K; Sonoo H; Kurebayashi J; Nomura T; Ohkubo S; Yamamoto Y; Yamamoto S
    Clin Cancer Res; 2002 May; 8(5):1125-31. PubMed ID: 12006528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor angiogenesis inhibitors.
    Kiselev SM; Lutsenko SV; Severin SE; Severin ES
    Biochemistry (Mosc); 2003 May; 68(5):497-513. PubMed ID: 12882631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.
    Foglieni C; Pagano K; Lessi M; Bugatti A; Moroni E; Pinessi D; Resovi A; Ribatti D; Bertini S; Ragona L; Bellina F; Rusnati M; Colombo G; Taraboletti G
    Sci Rep; 2016 Mar; 6():23432. PubMed ID: 27000667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review).
    Salinas-Vera YM; Marchat LA; Gallardo-Rincón D; Ruiz-García E; Astudillo-De La Vega H; Echavarría-Zepeda R; López-Camarillo C
    Int J Mol Med; 2019 Feb; 43(2):657-670. PubMed ID: 30483765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
    Valentine A; O'Rourke M; Yakkundi A; Worthington J; Hookham M; Bicknell R; McCarthy HO; McClelland K; McCallum L; Dyer H; McKeen H; Waugh DJ; Roberts J; McGregor J; Cotton G; James I; Harrison T; Hirst DG; Robson T
    Clin Cancer Res; 2011 Mar; 17(5):1044-56. PubMed ID: 21364036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sialic acid as a target for the development of novel antiangiogenic strategies.
    Chiodelli P; Urbinati C; Paiardi G; Monti E; Rusnati M
    Future Med Chem; 2018 Dec; 10(24):2835-2854. PubMed ID: 30539670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.
    Rofstad EK; Henriksen K; Galappathi K; Mathiesen B
    Cancer Res; 2003 Jul; 63(14):4055-61. PubMed ID: 12874006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous regulators of angiogenesis--emphasis on proteins with thrombospondin--type I motifs.
    Carpizo D; Iruela-Arispe ML
    Cancer Metastasis Rev; 2000; 19(1-2):159-65. PubMed ID: 11191055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice.
    Liu P; Wang Y; Li YH; Yang C; Zhou YL; Li B; Lu SH; Yang RC; Cai YL; Tobelem G; Caen J; Han ZC
    Leuk Res; 2003 Aug; 27(8):701-8. PubMed ID: 12801528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.
    Rofstad EK; Galappathi K; Mathiesen B
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):493-9. PubMed ID: 14751520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synopsis of angiogenesis inhibitors in oncology.
    Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
    Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.